GlaxoSmithKline Stock Today

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;padding-top: 25px;;'>GP</div>
GlaxoSmithKline PLC is trading at 41.05 as of the 2nd of July 2020. This is 0.47 percent increase since the beginning of the trading day. The stock's last reported lowest price was 40.95. GlaxoSmithKline PLC has about a 39 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 30 trading days. Equity ratings for GlaxoSmithKline PLC are calculated daily based on the scoring framework. The performance scores are derived for the period starting the 3rd of April 2020 and ending today, the 2nd of July 2020. Click here to learn more.
Analyze Filter   Report: 22nd of July 2020

   Performance
7 100 

   Odds of Distress
39  

GlaxoSmithKline PLC Profile

Upcoming quarterly report is expected on the 22nd of July 2020. GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GlaxoSmithKline PLC operates under Drug Manufacturers - General classification in the United States and is traded on BATS Exchange. It employs 99437 people. more on GlaxoSmithKline PLC
GlaxoSmithKline PLC Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
GlaxoSmithKline PLC SEC Filings
GlaxoSmithKline PLC SEC Filings
Security & Exchange Commission EDGAR ReportsView All
Legal NameGlaxoSmithKline PLC
CEOEmma WalmsleyView All
Thematic Classification
Currently Active Investing Idea
  Drugs
View All
Average Analyst Recommendation
Current trade recommendation based on an ongoing consensus estimate among financial analysis covering GlaxoSmithKline PLC. The GlaxoSmithKline consensus assessment is calculated by taking the average estimates from all of the analysts covering GlaxoSmithKline PLC
Piotroski F Score
Academic score (developed by Joseph Piotroski in 2002) to determine the current strength of GlaxoSmithKline PLC financial position. Scores of 8 and 9 are usually clasified strong value stocks whereas scores of 2 or below are considered weak value stocks.
 7 - StrongDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares5.9 B5.4 B
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares Diluted5.5 BB
Significantly Up
Increasing
Stable
Net Cash Flow from Operations9.6 B9.5 B
Slightly Up
Increasing
Slightly volatile
Total Assets71.3 B79.7 B
Moderately Down
Increasing
Slightly volatile
Total Liabilities57 B61.3 B
Significantly Down
Increasing
Slightly volatile
Current Assets19.7 B19.5 B
Slightly Up
Increasing
Slightly volatile
Current Liabilities22.5 B24.1 B
Significantly Down
Increasing
Slightly volatile
Total Debt27.1 B30.5 B
Fairly Down
Increasing
Slightly volatile
Return on Average Assets0.07180.067
Notably Up
Decreasing
Slightly volatile
Gross Margin0.630.649
Sufficiently Down
Decreasing
Slightly volatile
Asset Turnover0.50.49
Fairly Up
Decreasing
Slightly volatile
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of GlaxoSmithKline PLC available fundamental, technical, and predictive indicators. Current horizon is 30 days (very short) - details
Cautious HoldUndervalued
Financial Strength
GlaxoSmithKline PLC financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to GlaxoSmithKline PLC success along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
A+ ( Average Bond Rating ) Very Firm
  Operating Cash Flow
GlaxoSmithKline PLC (GSK) is traded on BATS Exchange in USA. It is located in 980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom and employs 99,437 people. GlaxoSmithKline PLC is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with total capitalization of 117.89 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate GlaxoSmithKline PLC's market, we take the total number of its shares issued and multiply it by GlaxoSmithKline PLC's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. GlaxoSmithKline PLC runs under Healthcare sector within Drug Manufacturers?General industry. The entity has 2.49 B outstanding shares of which 8.01 M shares are currently shorted by investors with about 2.57 days to cover shorted positions. GLAXOSMITHKLINE P has about 5.12 B in cash with (5.78 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.08.
Check GlaxoSmithKline PLC Probability Of Bankruptcy

Ownership Allocation (%)

GlaxoSmithKline Stock Price Odds Analysis

Odds Down 41.05HorizonTargetOdds Up 41.05
54.29%30 days
 41.05 
45.41%
Based on a normal probability distribution, the odds of GlaxoSmithKline PLC to move above the current price in 30 days from now is about 45.41 (This GlaxoSmithKline PLC probability density function shows the probability of GlaxoSmithKline PLC Stock to fall within a particular range of prices over 30 days) .

GlaxoSmithKline Stock Institutional Holders

InstituionSecurity TypeTotal SharesValue
Dodge CoxCommon Shares44 M1.7 B
Renaissance Technologies LlcCommon Shares23.1 M874.4 M
View GlaxoSmithKline PLC Diagnostics

GlaxoSmithKline PLC Income Statement Over Time

GlaxoSmithKline PLC Income Statement is one of the three primary financial statements used for reporting GlaxoSmithKline's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of GlaxoSmithKline PLC revenue and expense. GlaxoSmithKline PLC Income Statement primarily focuses on the company's revenues and expenses during a particular period. GlaxoSmithKline PLC Operating Expenses is increasing as compared to previous years. The last year's value of Operating Expenses was reported at 14.93 Billion. The current Revenues is estimated to increase to about 33.9 B, while Cost of Revenue is estimated to decrease to under 11.4 B. View More Fundamentals

GlaxoSmithKline Stock Against Markets

Did you try this?

Run Equity Forecasting Now

   

Equity Forecasting

Use basic forecasting models to generate price predictions and determine price momentum
All  Next Launch Module

GlaxoSmithKline PLC Upcoming and Recent Events

GlaxoSmithKline PLC Company Earnings Announcements Dates

Upcoming Quarterly Report22nd of July 2020
Next Earnings Report4th of November 2020
Next Fiscal Quarter End30th of June 2020
Next Fiscal Year End3rd of February 2021
Last Quarter Report31st of March 2020
Last Earning Anouncement30th of June 2019

GlaxoSmithKline PLC Corporate Filings

GlaxoSmithKline PLC SEC Reporting

Unclassified Corporate Event
View
Other Events
View

GlaxoSmithKline PLC Distributions to stockholders

A dividend is the distribution of a portion of GlaxoSmithKline PLC earnings, decided and managed by the GlaxoSmithKline PLCs board of directors and paid to a class of its shareholders. Note, announcements of dividend payouts are generally accompanied by a proportional increase or decrease in a company's stock price. GlaxoSmithKline PLC dividend payments follow a chronological order of events, and the associated dates are important to determine the shareholders who qualify for receiving the dividend payment.
14th of May 2020
20th of February 2020
14th of November 2019
8th of August 2019
16th of May 2019
21st of February 2019
15th of November 2018
9th of August 2018
Please check Risk vs Return Analysis. Please also try Equity Valuation module to check real value of public entities based on technical and fundamental data.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page